Studieoverzicht
BOOG nr.: |
Status: ( View all )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2017-03 SONIA | Open | Advanced/metastatic | HER2- HR+ | Not applicable | ||||||||||||||
2017-02 PERIDENO | Submitted (METC) | Adjuvant | HER2-, any HR | Postmenopausal | ||||||||||||||
2017-01 NEOLBC | Open | Neoadjuvant | HER2- HR+ | Postmenopausal | ||||||||||||||
2016-03 PRECISE | Open | Adjuvant | Not applicable | Not applicable | ||||||||||||||
2016-02 PALLAS | Open | Adjuvant | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2016-01 TOP-1 | Open | Data registration | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-03 POSITIVE | Open | Adjuvant | Any HER2, HR+ | Premenopausal | ||||||||||||||
2015-02 MonaLEEsa-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-01 Monarch-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2014-05 INFLAME | Open | Data registration | Not applicable | Not applicable | ||||||||||||||
2014-04 LORD | Open | Locoregional | Not applicable | Both pre- and postmenopausal | ||||||||||||||
2014-03 OLYMPIA | Open | Adjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2014-02 BRAVO | Follow up | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2014-01 MONALEESA-2 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-08 lumpectomie | Open | Locoregional | Not applicable | Not applicable | ||||||||||||||
2013-07 mastectomie | Open | Locoregional | Not applicable | Not applicable | ||||||||||||||
2013-06 Biomarker Study Everolimus | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-05 BELLE-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-04 DIRECT | Follow up | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-03 PERNETTA | Follow up | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-02 Male BC prospectief | Follow up | Data registration | Not applicable | Not applicable | ||||||||||||||
2013-01 Triple-B | Open | Advanced/metastatic | TNBC | Both pre- and postmenopausal | ||||||||||||||
2012-03 TRAIN-2 | Follow up | Neoadjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2012-02 SafeHer | Follow up | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2012-01 BALLET | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2011-02 APHINITY | Follow up | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2011-01 Abiraterone | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2010-05 SUBMIT | Closed | Advanced/metastatic | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-04 D-Care | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-03 RAPCHEM | Open | Locoregional | Not applicable | Not applicable | ||||||||||||||
2010-02 STOP&GO | Follow up | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-01 NEO-ZOTAC | Closed | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2009-05 BOLERO 2 | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2009-04 Male BC retrospectief | Closed | Data registration | Not applicable | Not applicable | ||||||||||||||
2009-03 DCIS | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2009-02 SNARB | Closed | Locoregional | Not applicable | Not applicable | ||||||||||||||
2009-01 IRMA | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2008-03 HAT | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2008-02 A6181099 | Closed | Advanced/metastatic | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2008-01 2-2-6 G-CSF | Closed | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2007-02 INTENS | Closed | Neoadjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2007-01 ALTTO | Follow up | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-07 MIRROR | Closed | Not applicable | Not applicable | Not applicable | ||||||||||||||
2006-06 ATX | Closed | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-05 IDEAL | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-04b TEAM IIb | Closed | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-04a TEAM IIa | Closed | Neoadjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-03 SUPREMO | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2006-02 OMEGA | Closed | Advanced/metastatic | Any HER2, any HR | Postmenopausal | ||||||||||||||
2006-01 DATA | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2005-03 MINDACT | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2005-02 MATADOR | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2004-02 TBP | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2004-01 Young Boost | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2003-04 Pregnancy | Follow up | Not applicable | Any HER2, any HR | Premenopausal | ||||||||||||||
2003-02 Calor | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2002-04 HERA | Closed | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2002-02 Hertax | Closed | Advanced/metastatic | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2001-02 AMAROS | Closed | Locoregional | Not applicable | Not applicable | ||||||||||||||
2001-01 TEAM | Closed | Adjuvant | Any HER2, HR+ | Postmenopausal |